Regeneron Pharmaceuticals, Inc. (REGN) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$720.78
Price Target
$865.68
Target Range
$700.00 — $1057.00
Analyst Rating
Buy
Forward P/E15.6x
Trailing P/E17.4x
Forward PEG2.47
Implied Growth+12.5%
Median Target$873.00
Analyst Spread41.2%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$700
-2.9%
Consensus
$866
+20.1%
Bull Case
$1057
+46.6%
Valuation Model TargetsConfidence: 57/100
Bear$594
Base$925
Bull$2324
REGN Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Regeneron Pharmaceuticals, Inc. (REGN) has a Wall Street consensus price target of $865.68, based on estimates from 48 covering analysts. With the stock currently trading at $720.78, this represents a potential upside of +20.1%. The company has a market capitalization of $74.89B.
Analyst price targets range from a low of $700.00 to a high of $1057.00, representing a 41% spread in expectations. The median target of $873.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 34 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, REGN trades at a trailing P/E of 17.4x and forward P/E of 15.6x. The forward PEG ratio of 2.47 reflects a premium valuation. Analysts expect EPS to grow +12.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $925.03, with bear and bull scenarios of $594.28 and $2323.69 respectively. Model confidence stands at 57/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+20.8%
Avg Forward P/E16.6x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 BIIBBiogen Inc. | $28.2B | $190.68 | $211.42 | +10.9% | Buy | 13.0x | 48 |
 VRTXVertex Pharmaceuticals Incorporated | $108.8B | $427.65 | $552.27 | +29.1% | Buy | 22.3x | 56 |
 INCYIncyte Corporation | $19.9B | $99.85 | $109.50 | +9.7% | Buy | 13.3x | 44 |
 BMRNBioMarin Pharmaceutical Inc. | $10.5B | $54.60 | $89.64 | +64.2% | Buy | 12.7x | 41 |
 ABBVAbbVie Inc. | $362.6B | $204.98 | $256.64 | +25.2% | Buy | 14.4x | 41 |
 LLYEli Lilly and Company | $932.6B | $987.11 | $1258.47 | +27.5% | Buy | 28.6x | 45 |
 AMGNAmgen Inc. | $178.7B | $331.11 | $350.76 | +5.9% | Buy | 14.8x | 38 |
 GILDGilead Sciences, Inc. | $169.8B | $136.30 | $161.88 | +18.8% | Buy | 15.9x | 58 |
 MRKMerck & Co., Inc. | $280.5B | $113.56 | $129.31 | +13.9% | Buy | 22.2x | 37 |
 PFEPfizer Inc. | $150.8B | $26.50 | $27.27 | +2.9% | Hold | 9.0x | 39 |
Upside Potential Comparison
BMRNVRTXLLYABBVGILDMRKBIIBINCYFull REGN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See REGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs REGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare REGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonREGN — Frequently Asked Questions
Quick answers to the most common questions about buying REGN stock.
What is the REGN stock price target for 2026?
The consensus Wall Street price target for REGN is $865.68, representing 20.1% upside from the current price of $720.78. With 48 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is REGN a buy, sell, or hold?
REGN has a consensus rating of "Buy" based on 48 Wall Street analysts. The rating breakdown is predominantly bullish, with 34 Buy/Strong Buy ratings. The consensus 12-month price target of $865.68 implies 20.1% upside from current levels.
Is REGN stock overvalued or undervalued?
With a forward P/E of 15.6017x, REGN trades at a relatively low valuation. The consensus target of $865.68 implies 20.1% appreciation, suggesting meaningful undervaluation.
How high can REGN stock go?
The most bullish Wall Street analyst has a price target of $1057 for REGN, while the most conservative target is $700. The consensus of $865.68 represents the median expectation. Our quantitative valuation model projects a bull case target of $2324 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover REGN stock?
REGN is heavily covered by Wall Street, with 48 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 34 have Buy ratings, 14 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the REGN stock forecast?
The 12-month REGN stock forecast based on 48 Wall Street analysts shows a consensus price target of $865.68, with estimates ranging from $700 (bear case) to $1057 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $925, with bear/bull scenarios of $594/$2324.
What is REGN's fair value based on fundamentals?
Our quantitative valuation model calculates REGN's fair value at $925 (base case), with a bear case of $594 and bull case of $2324. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 57/100.
What is REGN's forward P/E ratio?
REGN trades at a forward P/E ratio of 15.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 17.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy REGN stock?
Wall Street analysts are very optimistic on REGN, with a "Buy" consensus rating and $865.68 price target (20.1% upside). 34 of 48 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do REGN price targets vary so much?
REGN analyst price targets range from $700 to $1057, a 41% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $865.68 consensus represents the middle ground. Our model's $594-$2324 range provides an independent fundamental perspective.